Canada

Search form

The Panther Fusion MRSA assay

The Panther Fusion MRSA assay is designed for the qualitative detection and differentiation of Staphylococcus aureus (SA) and methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. It is intended to aid in the prevention and control of SA and MRSA infections in healthcare settings.

The Panther Fusion MRSA assay allows for direct loading of ESwab nasal samples on the Panther Fusion system. It has broad strain inclusivity, including the Bengal Bay clone. It also correctly identifies empty cassette variants.1

Overview

Elevate Your Laboratory

There are several key takeaways for laboratory success with the Panther Fusion MRSA assay. The Panther Fusion MRSA assay has advantages when compared with culture, laboratory-developed tests and other IVDs.2

Labor and Time Savings

Load samples and walkaway to free up staff for other activities. Streamline the pathway for MRSA testing and eliminate the need to enrich samples for molecular testing. Random access capabilities enhance infection control efforts, saving time with batch-free processing.

Performance Benefits

Provide clinicians with fast and accurate results, allowing for better patient management and infection control.

Cost Implications

Reduce costly operator errors and re-tests with system process checks to ensure accuracy. Fully automated testing means staff can focus on other activities during processing. Our ready-to-use, unit-dose format with 60-day onboard stability helps to reduce waste.

References

1. Panther Fusion MRSA assay [package insert]. AW-18028, Rev. 003. San Diego, CA: Hologic, Inc.; 2019. 2. Hologic, Inc. Data on File. 2018